Giuseppe Tonini
Research Subjects
Giuseppe Tonini has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Daniele Santini
Medical Oncology, University Campus Bio-Medico, 00128 Roma, Italy
397 shared publications - Bruno Vincenzi
University Campus Bio-Medico, Rome, Italy
348 shared publications - Francesco Pantano
Campus Bio-Medico University of Rome, Rome, Italy
188 shared publications - Giuseppe Perrone
Research Unit of Anatomical Pathology, Department of Medicine and Surgery, Università Campus Bio-Medico Di Roma, 00128 Rome, Italy
178 shared publications - Paolo Marchetti
Istituto Dermopatico dell'Immacolata,Rome,Italy, Italy
166 shared publications - Andrea Botticelli
Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, 00185 Rome, Italy
155 shared publications
Latest Publications
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
Supplementary Figure S3. Figure showing overall survival in liquid only group.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
Supplementary Figure S3. Figure showing overall survival in liquid only group.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
Supplementary Figure S9. Differences in variant coverage between tissue and liquid tests (Venn diagram).
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
Supplementary Figure S9. Differences in variant coverage between tissue and liquid tests (Venn diagram).
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
Supplementary Figure S1. Figure showing overall survival in the tissue only group.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
Supplementary Figure S1. Figure showing overall survival in the tissue only group.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
Supplementary Table S1. Representativeness of Study Participants.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
Supplementary Table S1. Representativeness of Study Participants.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
Supplementary Figure S5. Figure showing overall survival in discordant group.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
Supplementary Figure S5. Figure showing overall survival in discordant group.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
Supplementary Figure S2. Figure showing progression-free survival in the tissue only group.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
Supplementary Figure S2. Figure showing progression-free survival in the tissue only group.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
Supplementary Figure S7. Figure showing concordance/discordance rates based on primary tumor.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
Supplementary Figure S7. Figure showing concordance/discordance rates based on primary tumor.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
Supplementary Figure S6. Figure showing progression-free survival in the discordant group.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
Supplementary Figure S6. Figure showing progression-free survival in the discordant group.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
Supplementary Figure S4. Figure showing progression-free survival in liquid only group.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
Supplementary Figure S4. Figure showing progression-free survival in liquid only group.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
Supplementary Figure S8. Figure showing concordance and discordance rates based on site of genomic profiling.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
Supplementary Figure S8. Figure showing concordance and discordance rates based on site of genomic profiling.